Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 2/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 2/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28901520 | 0.94 | TXNRD1 (0.47) | TXNRD1GPR119METNAMPTPOLB | |
| SCHEMBL21247447 | 0.94 | TXNRD1 (0.47) | TXNRD1GPR119METNAMPTPOLB | |
| SCHEMBL28469711 | 0.94 | TXNRD1 (0.47) | TXNRD1GPR119METNAMPTPOLB | |
| SCHEMBL28480884 | 0.88 | MET (0.42) | TXNRD1GPR119METPOLB | |
| SCHEMBL17362388 | 0.83 | GPR119 (0.52) | GPR119NAMPTPOLBSTS | |
| SCHEMBL1420930 | 0.81 | GPR119 (0.52) | GPR119METPOLBALDH1A1LMNA | |
| SCHEMBL21247456 | 0.80 | TXNRD1 (0.47) | TXNRD1ALDH1A1LMNAMAPTPAX8 | |
| SCHEMBL20471643 | 0.80 | TXNRD1 (0.47) | TXNRD1ALDH1A1LMNAMAPTPAX8 | |
| SCHEMBL20471639 | 0.80 | TXNRD1 (0.47) | TXNRD1ALDH1A1LMNAMAPTPAX8 | |
| SCHEMBL14335007 | 0.79 | GPR119 (0.53) | GPR119POLBALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111867587-A | Thioredoxin reductase inhibitors for the treatment of cancer | 信达制药公司 | 2020-10-30 | — | — | CN | disclosed |